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Available online 22 September 2017Background: In a placebo-controlled trial of the peptide-based therapeutic HIV-1 p24Gag vaccine candidate Vacc-
4x, participants on combination antiretroviral therapy (cART) received six immunizations over 18weeks, follow-
ed by analytical treatment interruption (ATI) between weeks 28 and 52. Cell-mediated immune responses were
investigated as predictors of Vacc-4x effect (VE) on viral load (VL) and CD4 count during ATI.
Methods: All analyses of week 28 responses and fold-changes relative to baseline considered per-protocol partic-
ipants (Vacc-4x:placebo= 72:32) resuming cART after week 40. Linear regression models with interaction tests
were used. VE was estimated as the Vacc-4x–placebo difference in log10-transformed VL (VEVL) or CD4 count
(VECD4).
Findings: A lower fold-change of CD4+ T-cell proliferation was associated with VECD4 at week 48 (p = 0.036,
multiplicity adjusted q= 0.036) and week 52 (p=0.040, q = 0.080). A higher fold-change of IFN-γ in prolifer-
ation supernatants was associated with VEVL at week 44 (p= 0.047, q = 0.07). A higher fold-change of TNF-α
was associated with VEVL at week 44 (p = 0.045, q = 0.070), week 48 (p = 0.028, q = 0.070), and week 52
(p = 0.037, q = 0.074). A higher fold-change of IL-6 was associated with VEVL at week 48 (p = 0.017, q =
0.036). TNF-α levels (Nmedian) were associated with VECD4 at week 48 (p= 0.009, q = 0.009).
Interpretation: These exploratory analyses highlight the potential value of investigating biomarkers in T-cell pro-
liferation supernatants for VE in clinical studies.77Vi
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CD41. Introduction
Vacc-4x is a peptide-based therapeutic human immunodeﬁciency
virus (HIV)-1 vaccine candidate, that aims to induce cell-mediated im-
mune responses to conserved regions of p24Gag. Vacc-4x is adminis-
tered intradermally for uptake by dendritic cells in the presence of
granulocyte-macrophage colony stimulating factor (GM-CSF). Dendritic
cells are potent antigen presenting cells that have the capacity for cross
presentation allowing for epitope presentation on human leukocyte an-
tigen (HLA) classes I and II. Following peptide uptake and intracellularka, NO-0116, Oslo, Norway.
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is an open access article underproteolytic processing within dendritic cells, presentation of conserved
epitopes on HLA class II stimulates CD4+ T cells. Moreover, presenta-
tion of epitopes on HLA class I stimulates CD8+ T cells, which can
then kill infected cells presenting these conserved epitopes. Since
sustained cytolytic effects of CD8+ T-cells require immune help from
CD4+ T-cells, Vacc-4x carries both HLA class I and class II epitopes. Ef-
fective cell-mediated immune responses that can control and/or reduce
virus levels, maymaintain CD4+T-cell counts and/or slow their decline
during analytical treatment interruption (ATI).
Vacc-4x was shown to be safe and immunogenic in a randomized,
double-blind, placebo-controlled phase 2 clinical study enrolling 137
HIV-1-infected participants who were virologically suppressed on
combination antiretroviral therapy (cART) (Pollard et al., 2014). Six
immunizations were given between week 1 (baseline) and week 18
while participants continued cART. At week 28 eligible participants
underwent ATI and were removed from cART for up to six months
until week 52. Although no differences between the treatment groupsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in CD4 count change during ATI) were observed, there was a signiﬁcant
reduction in viral load (VL) set-point (Pollard et al., 2014) and better
preserved CD4 counts (Huang et al., 2016a) in the Vacc-4x group com-
pared to placebo. In addition, both groups demonstrated increases from
baseline in HIV-1-speciﬁc IFN-γ-secreting peripheral bloodmononucle-
ar cells (PBMCs) against p24 antigens by Enzyme-linked ImmunoSpot
(ELISPOT) assay at week 52; however, only in the Vacc-4x group was
this increase associated with a statistically signiﬁcant reduction in VL
set-point compared to the placebo group during ATI (Pollard et al.,
2014). This ﬁnding suggests the quality of cell-mediated immune re-
sponses (CMIs) during ATI may have differed between the two treat-
ment groups and that speciﬁc CMIs elicited by Vacc-4x contributed to
the beneﬁcial Vacc-4x effect (VE) on VL and CD4 count.
The objective of this studywas to followupon theprior observations
by systematically assessing CMIs at week 28 relative to baseline (wk28/
wk1) or on their own (week 28) as predictors of VE during ATI. We hy-
pothesized that T-cell immunity in terms of the magnitude and/or the
presence (yes or no) of immune biomarkers (with or without reference
to baseline values), especially those related to immune stimulation, T-
cell proliferation and inﬂammation would predict the effect of Vacc-4x
(vs. placebo) on controlling VL and/or maintaining CD4 count during
ATI. To address these hypotheses, we considered immune biomarkers
including interferon-gamma (IFN-γ) secreting T-cells measured by
ELISPOT, CD4+ and CD8+ and Total (CD3+) T-cell proliferation mea-
sured by a carboxyﬂuorescein succinimidyl ester (CFSE) assay, and cyto-
kines released from T-cell proliferation supernatants ex vivo measured
by the Luminex assay.2. Materials and Methods
2.1. Study Procedures
The Vacc-4x study took place between July 2008 and June 2010 in
Spain, Italy, the USA, the UK, and Germany (Pollard et al., 2014). Partic-
ipants aged 18–55 years and virologically-suppressed on cART prior to
enrollmentwere randomized to receive four weekly Vacc-4x or placebo
priming immunizations and two boosting immunizations at weeks 16
and 18, followed by ATI by week 28. During ATI, participants returned
to cART if their CD4 count reached 350 cells/μl or fell by 50%. Pre-ART
VL and CD4 count were also available for most participants. All partici-
pants in the study had provided informed consent, and the study proto-
col had been approved by all participating regional ethics committees.
Full inclusion criteria can be found at www.clinicaltrials.gov under the
identiﬁer NCT00659789.2.2. Immunological and Safety Measurements
CMIs to p24 antigens were measured at weeks 1 and 28 in PBMCs
using ELISPOT and T-cell proliferation assays [CFSE staining]. Cytokine
and chemokine concentrations were assessed in proliferation superna-
tants using a Bioplex 200 Luminex machine (Bio-Rad, Hercules, CA). A
total of 22 continuous and 30 binary immune variables based on im-
mune responses measured at week 28 relative to baseline (wk28/wk1
fold-change) or on their own (week 28) were evaluated.
Safety measurements, e.g. lactose dehydrogenase (LDH), white
blood cell (WBC) and anti-C5/gp41732–744 antibody levels which target
a region on HIV-1 envelope glycoporteins, were also determined at
baseline and over time. Antibodies to the 5th constant (C5) domain of
HIV-1 envelope glycoproteins and a part of the transmembrane glyco-
protein gp41, (gp41732–744), were tested because they have been
shown to be associated with moderate viral load and slower disease
progression, suggesting they may have an impact upon HIV-associated
immune activation (Sørensen et al., 2017).2.2.1. Peptides and Protein Antigens
Peptideswere synthesized at Schafer-N (Copenhagen, Denmark). All
peptides used for in vitro immunological analyses were ﬁrst re-
suspended in DMSO and then water. Recombinant p24 core protein,
HTLV IIIB was obtained from Bioprocess Pty Ltd. Staphylococcal entero-
toxin B (SEB) (200 ng/mL) and media containing DMSO concentrations
equivalent to those in the peptide pool wells were used as positive and
negative controls, respectively. The p24 antigens used in these analyses
were overlapping 15-mer peptides offset by 2 amino acids correspond-
ing to the region on p24 covered by Vacc-4x. In addition, full length re-
combinant p24 protein clade B was used.
2.2.2. Preparation of Peripheral Blood Mononuclear Cells (PBMCs)
T-cell responses were evaluated from PBMCs prepared at each par-
ticipating site. After collection, all PBMCs were frozen at−80 °C and
shipped to the central laboratory at CHUV, Switzerland within 21 days
for storage in liquid nitrogen. The same batch of fetal bovine serum
(FBS) was used for all sites to reduce inter-laboratory variation. All
sites preparing PBMCs were accredited prior to the study start and
their ability to prepare PBMCs with recovery N70% and viability N80%
on thawing was conﬁrmed (Boaz et al., 2009).
Ex vivo interferon-γ (IFN-γ) secretion was examined in thawed
PBMCs following stimulation with p24 antigens using an ELISPOT
assay, T-cell proliferationwas examined using a CFSE assay as described
in Pollard et al. (2014), and cytokine/chemokine production was
assessed in proliferation supernatants using a Luminex assay at weeks
1 and 28.
2.2.3. ELISPOT Assay Criteria
ELISPOT assays were considered valid if the mean of triplicate wells
did not exceed 50 spot forming units (SFUs)/106 PBMCs in the negative
control (medium) and N500 SFUs/106 PBMCs in the positive control
(SEB). Three ELISPOT assay immune variables were assessed as predic-
tors of vaccine effect: fold-change of the mean SFU in the stimulated
over the negative control as well as a continuous biomarker, fold-
change of the mean SFU above or below the median value, and the pro-
tocol–deﬁned response positivity as dichotomized variables. Assay re-
sponses were deﬁned positive if the mean SFU in stimulated was four
times or greater than the negative control and at least 55 SFUs per 106
PBMCs (Bart et al., 2008; Harari et al., 2008).
2.2.4. T-Cell Proliferation Assays (CFSE)
T-cell proliferation was assessed ex vivo in CD4+ and CD8+ T-cells,
as well as in the total T-cell population (CD3+), using a CFSE assay
(Cellerai et al., 2010; Perreau et al., 2011). Staphylococcal enterotoxin
B (SEB) stimulation and medium alone served as positive and negative
controls, respectively (Harari et al., 2008). Three CFSE assay immune
variables were assessed as predictors of vaccine effect: fold-change of
percent CFSE lowdividing cells (CFSELo) in the stimulated over the neg-
ative control wells as a continuous biomarker, fold-change of percent
CFSElo above or below the median value, and the protocol-deﬁned re-
sponse positivity as dichotomized variables. Assay responses were de-
ﬁned as positive if the percentage CFSElo dividing cells reactive to p24
antigenswas three times or greater than the percentage CFSE low divid-
ing cells in the negative (medium) control (Harari et al., 2008).
2.2.5. Cytokine Measurements by Luminex
In addition, supernatants from proliferation assays were frozen for
subsequent Luminex assays. Upon thawing, the concentrations of 27
chemokines/cytokines (pg/mL levels) in the thawed supernatants
were determined upon recombinant p24 stimulation using the Luminex
platform (BioRad Inc.; Hercules, CA). Among these markers, the follow-
ing had an appropriate dynamic range andwere evaluated as predictors
of vaccine effect: IFN-γ, tumor necrosis factor (TNF)-α, T-helper (Th)1,
interleukin (IL)-14, IL-13, and Th2; the immune modulators IL-10
and IL-17; and the inﬂammatory markers IL-6 and macrophage
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cytokines were excluded from further analysis due to lack of variation
across individuals: IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-7, IL-8, IL-9, IL-
12p70, IL-15, Eotaxin, ﬁbroblast growth factor (FGF)-basic, granulocyte
colony stimulating factor (G-CSF), granulocyte macrophage colony
stimulating factor (GM-CSF), interferon gamma-induced protein (IP)-
10, monocyte chemoattractant protein (MCP)-1, MIP-1α, platelet de-
rived growth factor (PDGF)-β, regulated on activation, normal T-cell
expressed and secreted (RANTES), and vascular endothelial growth fac-
tor (VEGF). For each immune marker, two immune variables were
assessed as predictors of vaccine effect: fold-change of concentration
in the stimulated over the negative control as a continuous biomarker,
and the fold-change above or below the median.
2.3. Statistical Analyses
All analyses were conducted in the subset of per-protocol (PP) par-
ticipants who did not resume cART until after week 40 (Vacc-4x n =
72; placebo n = 32) (Fig. 1, Fig. S1) (Pollard et al., 2014). This time
point was at least 12 weeks after cART interruption; thus, participants
had experienced peak viremia rebound by then (Kutzler and Jacobsen,
2008). The VL and CD4 count endpoints were log10-transformed VL
and CD4 count at weeks 44, 48, and 52 during ATI, with and without
subtracting log10-transformed pre-ART VL and CD4 count, respectively.
VE onVL (VEVL) and CD4 count (VECD4)were deﬁned as themean differ-
ence of VL and CD4 count endpoints, respectively, between the Vacc-4x
and placebo groups. A positive (or negative) immune predictor indi-
cates a positive (or negative) association between immune response
levels and Vacc-4x beneﬁt. Vacc-4x beneﬁt is indicated by having a
lower VL or a higher CD4 count in the Vacc-4x group compared with
placebo.Fig. 1. CONSORT diagram showing the availability of immunological samples forFor each VL and CD4 count endpoint, univariate andmultivariable lin-
ear regressionmodels of observed complete-case datawere used to iden-
tify potential predictors of VE. Missing data due to insufﬁcient specimens
were assumed to bemissing completely at random.Wald testswere used
to evaluate statistical interactions between each immune variable predic-
tor and treatment assignment. All reported results are from multiple re-
gression models adjusted for at least one of the following baseline
confounding variables identiﬁed as predictors of theVL or CD4 count end-
point in the Vacc-4x or placebo group: preART VL or CD4,median-dichot-
omized LDH (for VL endpoints), continuous LDH (for preART-adjusted VL
endpoints), median-dichotomized WBC (for preART-adjusted VL end-
points), anti-C5/gp41732–744 antibodies, LDHorWBC (for CD4 endpoints),
or dichotomized WBC or anti-C5/gp41732–744 (for preART-adjusted CD4
endpoints). Sex at birth was also considered in the analyses of the Vacc-
4x group or the combined Vacc-4x and placebo groups. However, due
to the sparsity of female participants, especially in the placebo group,
analyses did not adjust for sex at birth when models were unstable.
When considering what baseline covariates might contribute to the anal-
ysis of immune responses as predictors of vaccine effect (our study objec-
tive), we ﬁrst examined all available baseline demographic and clinical
factors as potential predictors of VL and/or CD4 count during ATI within
each treatment group as previously described (Huang et al., 2016a). Spe-
ciﬁcally, we considered gender (male or female), age (both continuous
and dichotomized), country (Germany, Spain, US, or UK and Italy com-
bined), time on cART (continuous and dichotomized), time since HIV di-
agnosis (continuous and dichotomized), CD4 nadir (continuous and
dichotomized), preART VL (continuous and dichotomized), preART CD4
count (continuous and dichotomized), as well as host genetics class I
HLA type. Among these baseline factors, together with safety factors con-
sidered in a separate analysis (Huang et al., 2016b), age, gender, preART
VL, LDH and WBC were identiﬁed as signiﬁcant predictors of VL and/orthe vaccine effect prediction analysis of the phase 2 Vacc-4x clinical study.
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of vaccine effect predictors reported here. Other baseline factors were
found to be only marginally or not predictive and hence were not includ-
ed in further analysis.
Q-values were calculated to account for multiple comparisons
within the analysis of each endpoint and predictor type (continuous
or categorical) (Benjamini and Hochberg, 1995). Multiple testing ad-
justments for interaction tests were applied across immune variables
that were identiﬁed as a signiﬁcant predictor in either the individual
or combined treatment groups. Predictors with associated unadjusted
p-value b 0.05 and q-value b 0.1were considered strong evidence of sig-
nals for hypothesis-generating purposes. Longitudinal data analyses of
VL and CD4 count endpoints over time between week 36 and week 52
were also performed. Analyses were performed using R (version 3.2.1)
(R Core Team, 2015).
3. Results
3.1. Descriptive Summary of the Study Data
In the PP cohort, week 1 baseline immune responses were generally
highly correlated with week 28 immune responses of the same bio-
marker (Fig. 2). Therefore, we considered the fold-changes of week 28Fig. 2. Correlations between week 1 and week 28 immune responses in the Vacc-4x group (
Spearman correlation coefﬁcients are represented in color grade, where dark red indicates a
signiﬁcance of the correlation is reported as: p b 0.05 = *; p b 0.01 = **; and p b 0.001 = ***.immune responses relative to week 1 as potential predictors of VEVL
and VECD4, to control for pre-existing immune responses in this HIV-1-
infected study population. We also observed positive correlations at
week 28 across assays between ELISPOT responses and CFSE CD8+ or
total T-cell (CD3+) responses in the Vacc-4x group but not the placebo
group. This suggests that Vacc-4x immunizations may have impacted
not only themagnitude but also the coordination of immune responses,
consistentwith observations for other vaccines (e.g., Chung et al., 2015).
Sufﬁcient dynamic rangeswere observed for both thewk1/wk28 fold-
change (Figs. 3 and 4) and week 28 immune variables (Figs. S2 and S3),
supporting the planned regression analyses. Statistical power was damp-
ened by up to 48%missing data in some assays (Fig. 1), mainly caused by
challenges of obtaining sufﬁcient specimens from all study participants.
Among 22 wk28/wk1 fold-change immune variables, onemeasured
in PBMCs by the CFSE assay was identiﬁed as a negative predictor of
VECD4 at week 44, 48, and/or 52 and three in proliferation supernatants
were identiﬁed as positive predictors of VEVL (Table 1). These results are
detailed below.
3.2. CD4 T-Cell Proliferation as a Predictor of Vaccine Effect
We found that lower wk28/wk1 fold-change of CD4+ T-cell prolif-
eration was signiﬁcantly associated with better preserved week 48upper diagonal) and placebo group (lower diagonal). The direction and strength of the
perfect positive correlation and dark blue indicates a perfect negative correlation. The
Fig. 3.Distributions of immune response variables (wk28/wk1) in relation toWeeks 44, 48, and 52 VL values in the placebo and Vacc-4x groups. Each cell indicates themagnitude of each
variable (row) for each placebo or Vacc-4x recipient (column) in color grade, where darker red indicates a higher level and darker blue indicates a lower level. Gray shading indicates
missing data. The columns are ordered by Week 52 VL, separately within the placebo and Vacc-4x groups. Panel (a) shows mean-centered magnitude of each measurement in
standard deviation scale for each continuous marker in relation to VL (log10-scale); Panel (b) shows dichotomized status of each measurement based on median-cutoff (indicated with
a sufﬁx “med.bny”) or positivity (indicated with a sufﬁx “pos”) in relation to VL (log10-scale).
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(week 48: interaction p= 0.036, q = 0.036; week 52: interaction p=
0.040, q = 0.080) (Table 1, Fig. 5). For week 48, an estimated VECD4 of
0.14 (95% CI: 0.01, 0.27) log10 increase was observed in the mean CD4
count among Vacc-4x vs. placebo recipients whose wk28/wk1 CD4+
CFSE levels were below the median, and an estimated VECD4 of 0.06
(95% CI:−0.20, 0.08) log10 decrease otherwise. Forweek 52, an estimat-
ed VECD4 of 0.12 (95% CI: 0.002, 0.24) log10 increase was observed in the
mean CD4 count among Vacc-4x vs. placebo recipients whose wk28/
wk1 CD4+ CFSE levels were below the median, and an estimated
VECD4 of 0.07 (95% CI: −0.19, 0.06) log10 decrease otherwise
(Table 1). Similar patterns were observed for week 44 VECD4, though
not statistically signiﬁcant (Fig. 5). However, higher week 28 CD4 T-
cell proliferation (without adjusting for week 1 levels) was associated
with better preserved CD4 counts in the Vacc-4x group compared to
the placebo group at week 52 (Fig. S4; Table S1). This ﬁnding suggests
that baseline CD4+ T-cell proliferation levels may infer the immunecapacity of an HIV-infected participant and play an important role in
predicting VECD4.
3.3. IFN-γ Secretion in T-Cell Proliferation Supernatants as a Predictor of
Vaccine Effect
We also found that higher wk28/wk1 fold-change of IFN-γ secretion
in proliferation supernatants was associated with reduced week 44
VL in the Vacc-4x group vs. the placebo group (interaction p= 0.047,
q = 0.07) (Fig. 5, Table 1), with an estimated VEVL of 0.44 (95% CI:
−0.27, 1.15) log10 increase in the mean VL among Vacc-4x vs. placebo
recipients at the 25% percentile level, and an estimated VEVL of 0.38
(95% CI: -0.92, 0.17) log10 decrease at the 75th percentile level of the
wk28/wk1 IFN-γ secretion level (Table 1). Similar patterns were ob-
served for week 48 and 52 VEVL, though not statistically signiﬁcant, pos-
sibly due to small sample sizes (Fig. 5). However, higher week 28 IFN-γ
secretion levels were associated with increased week 44 VL (Table S1
Fig. 4.Distributions of immune response variables (wk28/wk1) in relation toWeeks 44, 48, and 52 CD4 count values in the placebo and Vacc-4x groups. Each cell indicates themagnitude
of eachmeasurement (row) for each placebo or Vacc-4x recipient (column) in color grade, where darker red indicates a higher level and darker blue indicates a lower level. Gray shading
indicates missing data. The columns are ordered by Week 52 CD4 count, separately within the placebo and Vacc-4x groups. Panel (a) shows mean-centered magnitude of each
measurement in standard deviation scale for each continuous marker in relation to CD4 count (log10-scale); Panel (b) shows dichotomized status of each measurement based on
median-cutoff (indicated with a sufﬁx “med.bny”) or positivity (indicated with a sufﬁx “pos”) in relation to CD4 count (log10-scale).
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mune capacity.
3.4. TNF-α Secretion in T-Cell Proliferation Supernatants as a Predictor of
Vaccine Effect
In addition, we found that higher wk28/wk1 fold-change of
TNF-α secretion in proliferation supernatants was signiﬁcantly
associated with reduced VL at all three time-points post week 40 in
the Vacc-4x group compared to the placebo group (Fig. 5) (week44: in-
teraction p=0.045, q=0.070;week48: p=0.028, q=0.077;week52:
p= 0.037, q = 0.074) (Table 1). At week 44, an estimated VEVL of 0.22
(95% CI:−0.33, 0.77) log10 increase was observed in the mean VL
among Vacc-4x vs. placebo recipients at the 25th percentile level, and
an estimated VEVL of 0.29 (95% CI:−0.81, 0.23) log10 decrease at the
75th percentile of the wk28/wk1 TNF-α secretion levels; at week 48,
an estimated VEVL of 0.35 (95% CI:−0.24, 0.94) log10 increase wasobserved in the mean VL among Vacc-4x vs. placebo recipients at the
25th percentile level, and an estimated VEVL of 0.25 (95% CI:−0.8,
0.31) log10 decrease at the 75th percentile of the wk28/wk1 TNF-α se-
cretion levels; at week 52, an estimated VEVL of 0.35 (95%
CI:−0.37,1.06) log10 increase was observed in the mean VL among
Vacc-4x vs. placebo recipients at the 25th percentile level, and an esti-
mated VEVL of 0.32 (95% CI:−1.0, 0.35) log10 decrease at the 75th per-
centile of the wk28/wk1 TNF-α secretion level (Table 1). Furthermore,
wk28/wk1 TNF-α levels above the median were associated with
improved preART-adjusted week 48 CD4 count (interaction p =
0.009; q=0.009) (Table S2, Fig. S6), andweek 28 TNF-α levelswere as-
sociated with preART-adjusted week 52 CD4 counts (interaction p =
0.024; q = 0.096) (Fig. S7; Table S3) between the Vacc-4x and placebo
groups. These results suggest a qualitative difference in response be-
tween the Vacc-4x and placebo groups since increasing IFN-γ and
TNF-α levels were not associated with lower VL or better preserved
CD4 count in the placebo group (data not shown).
Table 1
Summary of wk28/wk1 immunological predictors of Vacc-4x effect.
Assay Biomarker Endpoint Groupa Effectb (95% CI) Interaction p (q) value
Luminex IFN-γ Week 44 VL 25%-ile 0.444 (−0.265, 1.154) 0.047 (0.070)
75%-ile −0.376 (−0.921, 0.169)
TNF-α Week 44 VL 25%-ile 0.223 (−0.326, 0.772) 0.045 (0.070)
75%-ile −0.288 (−0.806, 0.231)
Week 48 VL 25%-ile 0.349 (−0.239, 0.936) 0.028 (0.077)
75%-ile −0.246 (−0.801, 0.308)
Week 52 VL 25%-ile 0.347 (−0.370, 1.064) 0.037 (0.074)
75%-ile −0.324 (−0.995, 0.347)
IL-6 binary Week 48 VL IL6 bmedian 0.572 (−0.122, 1.267) 0.017 (0.052)
IL6 ≥median −0.576 (−1.254, 0.101)
CFSE CD4+ binary Week 48 CD4 CD4+ bmedian 0.141 (0.013, 0.269) 0.036 (0.036)
CD4+ ≥median −0.062 (−0.203, 0.079)
Week 52 CD4 CD4+ bmedian 0.123 (0.002, 0.244) 0.040 (0.080)
CD4+ ≥median −0.065 (−0.193, 0.063)
a Group: for continuousmarkers, Group indicates the 25th and 75th percentiles of the identiﬁedmarker; for binarymarkers, Group indicates the dichotomized subgroups based on the
identiﬁed marker.
b Effect: the effect was estimated as the log10 difference between Vacc-4x and placebo in the given Group. P-values (b0.05) and q values (b0.1) were considered signiﬁcant.
201Y. Huang et al. / EBioMedicine 24 (2017) 195–2043.5. IL-6 Secretion in T-Cell Proliferation Supernatants as a Predictor of
Vaccine Effect
Lastly, we found that higher wk28/wk1 fold-change of IL-6 secretion
in the proliferation supernatants was associated with reduced VL at
week 48 in the Vacc-4x group compared to the placebo group (interac-
tion p = 0.017, q = 0.036), with an estimated VEVL of 0.57 (95% CI:
−0.12, 1.27) log10 increase in the mean VL among Vacc-4x vs. placebo
recipients at the 25% percentile level, and an estimated VEVL of 0.58
(95% CI:−1.26, 0.10) log10 decrease at the 75th percentile level of the
wk28/wk1 IL-6 secretion levels. Similar patterns were also observed
for VEVL at weeks 44 and 52, though not statistically signiﬁcant (Fig. 5).
Among 30 week 28 immune variables, besides CD4+T-cell prolifer-
ation levels and IFN-γ, TNF-αmentioned above, IL-13 secretion, IL-17
secretion, and total T-cell proliferation levelswere identiﬁed as negative
predictors of VEVL and/or VECD4 (Table S1), whereasMIP-1βwas identi-
ﬁed as a positive predictor of VECD4 (Table S1; Fig. S4). Furthermore, in-
creased MIP-1β secretion levels were associated with increased
preART-adjusted VECD4 (Fig. S7, Table S3). However, this ﬁnding was
heavily inﬂuenced by a few data points and should be interpreted
with caution.4. Discussion
Oneobjective of therapeutic HIV-1 vaccination is to facilitate durable
immune control of VL in the absence of cART, enabling improved pres-
ervation of CD4 counts (Pantaleo et al., 1993). Besides HLA class I alleles
and CCR5 mutations, no immune biomarkers have been reported to be
associated with either the natural control of HIV-1 VL (e.g. in elite con-
trollers) or intervention-induced (e.g. therapeutic vaccination) control
of HIV-1 VL. The Vacc-4x phase 2 study was one of the largest place-
bo-controlled clinical trials of a therapeutic HIV-1 vaccine and included
up to 6 months ATI, permitting establishment of a VL set-point. As pre-
viously reported, there was no difference in the time to viral rebound
between Vacc-4x and placebo groups, although the viral load set point
was signiﬁcantly lower for the Vacc-4x group compared to placebo,
and compared to their own preART levels. These ﬁndings suggest that
Vacc-4x immunization yielded potential vaccine beneﬁt through im-
proved cell-mediated immune responses to HIV compared to the place-
bo group (Pollard et al., 2014). The Vacc-4x phase 2 study therefore
provides a unique opportunity to carry out analyses to determine pro-
spective immune correlates of Vacc-4x effect.
Prior analysis of safety parameters in the Vacc-4x phase 2 study re-
vealed that lower post-vaccination C-reactive protein concentrations
in serum and higher anti-C5/gp41732–744 antibody levels were associat-
edwith VE in Vacc-4x participants (Huang et al., 2016b), suggesting thatlow immune activation and/or inﬂammation may facilitate attaining
vaccine effect. It was therefore of further interest to determine the effect
of CMIs on VE, including cytokine production from T-cell proliferation
supernatants that are not usually addressed in clinical trials of HIV-1
therapeutic or preventative vaccines.
Baseline anti-HIV immune response variability is a particular chal-
lenge in the ﬁeld of therapeutic HIV-1 vaccines because the varying
nature and magnitude of baseline immune responses to HIV-1 may in-
ﬂuence the ability to effectively detect vaccine-induced immunity. We
found that ELISPOT and CFSE responses at baselinewere highly correlat-
ed with week 28 responses. This ﬁnding suggests that the immune sys-
tems of individuals with higher baseline immune responses while still
on cARTmay bemore responsive to immune stimulation by vaccination
than those who had lower baseline immune responses. Similar ﬁndings
have beenmade regarding the presence of baseline delayed type hyper-
sensitivity (DTH) responses in an earlier Vacc-4x clinical study (Nyhus
et al., 2006). This observation may have important implications for fu-
ture therapeutic and preventative vaccine studies of potential correlates
of vaccine effect, because strong predictors of post-vaccination bio-
markers will greatly increase the statistical efﬁciency of such evalua-
tions (Follman, 2006; Gilbert et al., 2014).
Vacc-4x aims to induce CD8+ T-cell-mediated killing of infected
cells, however, this was not measured directly in this study because
such assays were less developed at the time the study was conducted.
T-cell proliferation is nevertheless considered a central parameter for
measuring the immunogenicity of interventions aimed at inducing
cell-mediated immunity and ultimately killing of infected cells. T-cell
proliferation is a complex process and immune markers associated
with T-cell proliferation leading to CD8-mediated killing are not fully
understood. We therefore assessed cytokines released during ex vivo
T-cell proliferation to determine whether it was possible to identify po-
tential biomarkers for T-cell proliferation associated with the produc-
tion of CD8+ T-cells that could lead to vaccine-associated reductions
in viral load.
Several positive week28/wk1 and week 28 predictors of vaccine ef-
fect were identiﬁed. Regarding PBMC biomarkers, we found that higher
week 28 CD4+ T-cell proliferation but lower wk28/wk1 fold-changes
were associated with Vacc-4x beneﬁt in terms of better preserved CD4
counts in the Vacc-4x group vs. the placebo group during ATI. This sug-
gests that vaccine-matched T-cell responses atweek 28maybemore fo-
cused towards conserved (vulnerable) regions of HIV-1 p24, hence
providing beneﬁt in maintaining CD4 counts in the Vacc-4x group as
compared to the placebo group. Meanwhile, lower wk28/wk1 fold-
changes may be a consequence of higher baseline response levels and
the relative difference among participants being greater at baseline
than week 28. Another possibility could be the potential effect of
Vacc-4x immunization on reducing HIV reservoirs in peripheral blood
Fig. 5. Distributions of VL or CD4 count by identiﬁedwk28/wk1 immunological predictors of vaccine effect. Panel (a) shows VL vs. wk28/wk1 Luminex IFN-γ and TNF-α; Panel (b) shows
the distribution of VL by treatment group for wk28/wk1 Luminex IL-6 b and ≥median (1.07 log10); Panel (c) shows the distribution of CD4 count by treatment group for wk28/wk1 CFSE
CD4+ b and ≥median (1.0 log10).
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et al., 2016). This could theoretically have resulted in lower viral burden
in PBMCs byweek 28 and T-cell proliferative responses that did not lead
to a fold-rise from baseline.
Regarding T-cell proliferation supernatant biomarkers, we found
that higher wk28/wk1 TNF-α fold-changes were associated with Vacc-
4x beneﬁt in terms of lower VL and better preserved pre-ART adjusted
CD4 counts. Such positive correlation was also observed for week 28
TNF-α and preART-adjusted CD4 counts. Moreover, higher wk28/wk1
IFN-γ fold-changes were associated with Vacc-4x beneﬁt in terms of
lower VL. Both TNF-α and IFN-γ are established Th1 cytokines that acti-
vate effector functions ofmacrophages, neutrophils andCD8+T-cells to
kill cells infectedwith intracellular pathogens. Ex vivo IFN-γ production
in PBMCs following antigen stimulation (e.g. ELISPOT) has been used asa standard measure of vaccine immunogenicity. However, it is now
clear that cytokines induced by vaccination rarely act alone, but rather
in concert which complicates identiﬁcation of immune correlates. For
example,measurements of IFN-γ alone have been insufﬁcient to predict
efﬁcacy for both tuberculosis (Mittrücker et al., 2007) and HIV
(Buchbinder et al., 2008). Indeed, in the STEP study of a preventive ad-
enovirus 5-vectored HIV vaccine, cell-mediated immune responses
asmeasured by IFN-γ ELISPOT, did not correlate with protection, rather,
more participants in the vaccinated group became infected (Buchbinder
et al., 2008). Subsequent efforts have focused on the induction of
polyfunctional T-cells producing more than one cytokine on antigen
stimulation as measured by intracellular cytokine staining (ICS)
(Burgers et al., 2009; Corey et al., 2009). Recently, alternate statistical
methods have been developed to address polyfunctional T-cell
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strong inverse correlations between CD8+ T-cell responses and HIV-1
infection risk in the efﬁcacy study of another preventive DNA/rAd5 vac-
cine (Janes et al., 2017). The T-cell responseswere based on intracellular
cytokine staining of T-cells producing IFN-γ, IL-2 and/or TNF-α.
Our ﬁndings nevertheless support the concept that induction of IFN-γ
and TNF-α cytokines during ex vivo T-cell proliferation, which involves
longer term culture of cells than for ELISPOT and ICS, may be associated
with virus control and/or preservation of CD4 count during ATI. As such,
cytokine analysis of T-cell proliferation supernatants could emphasize
the breadth of cytokines and chemokines released on antigen stimulation
and thereby serve to complement ELISPOT and ICS analyses that detect
cytokine production from individual cells following short term culture.
We also found that higher wk28/wk1 fold-changes of IL-6 in prolif-
eration supernatants were associated with VE. Interestingly, serum IL-
6 was associated with chronic immune activation and adverse events
during ATI in the SMART study, where participants underwent treat-
ment interruption in the absence of any therapeutic intervention
(El Sadr et al., 2006). In the Vacc-4x study, serum IL-6 levels remained
within normal range (Pollard et al., 2014). Our ﬁndings could therefore
suggest that transient IL-6 released during T-cell proliferation responses
is associated with virus control, but that persistent (serum-detectable)
IL-6 induction drives HIV replication and disease progression, particu-
larly in the absence of cART. Higher levels of week 28 IL-17 in the place-
bo group were associated with lower CD4 counts at week 44; the
converse was true for the Vacc-4x group. This is consistent with prior
observations where higher plasma levels of IL-17 were associated
with lower CD4 counts (b200 cells/mm3) in HIV-1-positive volunteers
(Saing et al., 2016). Higher week 28 IL-13 (proinﬂammatory cytokine)
levels above the median were also associated with higher VL at week
48 in the Vacc-4x group vs. the placebo group. Taken together, these
ﬁndings highlight the complexity of cytokine responses in vaccine stud-
ies where induction of some cytokines (e.g. IL-6, IFN-γ and TNF-α) in T-
cell proliferation supernatants is associatedwith Vacc-4x effectwhereas
induction of other cytokines (e.g. IL-13 and IL-17) did not. These re-
sponses sometimes conﬂict with reported cytokine levels measured in
serum or plasma and related to HIV pathogenesis, perhaps because
the in vivo measurements may be complicated by underlying immune
activation. These observations also emphasize the importance of includ-
ing placebo controls in clinical studies evaluating therapeutic vaccines.
ELISPOT and CFSE are functional assays that measure ex vivo im-
mune responses to antigen stimulation and can be compared between
pre- and post-vaccination time-points. The CFSE positivity criteria
were stringent compared to other clinical studies (Danta et al., 2008),
which may have inﬂuenced the extent of positive proliferation assay
responses obtained. Of note, the p24 antigens used in this study
corresponded only to the conserved regions in the vaccine, from
which there has been little reported immune escape following Vacc-
4x immunization (Kran et al., 2010). The Luminex assay analyzed
CFSE supernatants following stimulation with full-length recombinant
p24, and could therefore also have included responses to p24 epitopes
outside the conserved regions in Vacc-4x.
Limitations of this study include 1) limited sample size for well-
powered assessment of immune biomarkers as correlates of the ob-
served vaccine effect. The small number of female participants also hin-
dered assessment of the impact of gender. 2) The identiﬁed immune
biomarkers were only assessed as predictors of vaccine effect, not as
biomarkers in the causal pathway of the observed vaccine effect. Future
research is needed to determine the clinical implications of these
biomarkers. 3) Given the small sample size and the large number of
potential biomarkers, we only assessed each biomarker univariately.
Future research could examine biomarker interplay and their collective
inﬂuence on vaccine effect. 4) Limited specimen availability from
all time-points precluded more comprehensive characterization of vac-
cine-induced immune responses (e.g. T-cell exhaustion markers, and
ICS analysis).Nevertheless, to our knowledge, previous studies onHIV immune cor-
relates of protection are predominately in the ﬁeld of preventative HIV
vaccines, where baseline responses are absent (Thakur et al., 2012). In
our analyses, we presented results with andwithout accounting for base-
line responses, highlighting their unique role in predicting VE in the con-
text of therapeutic HIV vaccines. Furthermore, much focus of current
research remains on the induction of humoral responses, with emphasis
on broadly neutralizing antibodies. On the other hand, therapeutic vac-
cines have largely focused on the induction of cell-mediated immune re-
sponses. Immunogenicity following therapeutic vaccination has been
described with reductions in viral load (Vardas et al., 2012; Garcia et al.,
2013; Pollard et al., 2014), as well as with no or limited effects on the
rate of viral rebound or control of viral load (Jacobson et al., 2016;
Thompson et al., 2016). No immune correlates have yet been clearly de-
ﬁned from these generally small studies. Perera et al. (2016) evaluated
one HIV-1 elite controller, who had received a p24 therapeutic vaccine
in 1993. Responses associated with virus control included high fold-
changes in plasma levels of fractalkine, Interferon-inducible T-cell alpha
chemoattractant (I-TAC), insulin-like-growth factor binding protein
(IGFBP)-2, and MIP-1α. It is also not clear whether the correlates for
virus control (i.e. reducing viral load set point) are going to be the same
as those for delaying viral rebound. Our ﬁndings based on one of the larg-
est therapeutic HIV vaccine trials emphasize the importance of baseline-
adjusted correlation analyses of immunological markers, and the poten-
tial value of assessing cytokine production in T-cell proliferation superna-
tants harvested from ex vivo antigen stimulation in placebo-controlled
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